AKTUAPHARMA

Active

Public limited companyfounded 199828 yrs activeTerhulpsesteenweg 6A, 1560 Hoeilaart, BelgiumKBO/BCE: BE 0463.582.004

Summary

The computed 12-month bankruptcy probability of AKTUAPHARMA is 4.1% (elevated). The 2025 annual accounts show negative equity (€-3.18M) and a net result of €-115k. Equity is shrinking by ~2.8% per year across the filed fiscal years. The company has been active since 1998 and the Belgian State Gazette contains no insolvency or warning signals.

Watch Print / PDF

Checked score

No current score

Insufficient figures

A score requires measurable solvency, liquidity and profitability.

Bankruptcy probability: Elevated

Axes · tick = 2024

Profitability-

Solvency-

Growth32=

Track record100

Bankruptcy probability, 12 months

4.1% Elevated

0%0.5%1.5%4%10%≥ 25%

How do we compute the score and the probability?

Credit check for your own amount and term

Signals

Six signals. The signal on the left, the evidence on the right.

−lowers risk+raises risk○neutral

Annual accounts: weaker financial profile

The latest annual accounts show a weaker profile in solvency, result or liquidity than companies that stay afloat.

NBB · annual accounts 2025

No NACE activity registered

No NACE activity is registered in the KBO, which is more common among companies that later fail.

KBO · activities

Long track record

A company with a long track record statistically fails less often than a young one.

KBO · incorporation date

Age against the risk zone

Lower-risk legal form

Companies with this legal form statistically fail less often than a BV.

KBO · legal form

Negative equity

The 2025 annual accounts show negative equity and a net loss.

NBB · annual accounts 2025

Equity per financial year

181920232425

2018 to 2025 · latest year €-3.18M

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 07-07-2026, 24 days ahead of the deadline.

NBB · 10 filings

Deviation from the deadline

2025

24 d early

2024

34 d early

2023

34 d early

2022

21 d early

2021

24 d early

2020

18 d early

2019

22 d early

← before the deadline after the deadline →

Checked, nothing found (2)

The next deadline is still running

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.

Companies Code · seven months

Position in the running window

24-09-2026 today31-12-2026 close31-07-2027 deadline

No strike-offs in the KBO publications

We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

KBO publications · our coverage

Financials · fiscal year 2025, full schema

Turnover

Not included in this filing

EBIT margin

Not included in this filing

Net result

€-115k▲ 24.7%

2024 · €-153k

2018: €-36k 2019: €-37k 2020: €-32k 2023: €-123k 2024: €-153k

2018 → 2025

Working capital

€-2.71M▼ 1.2%

2019 · €-2.67M

2018: €-2.64M 2019: €-2.67M

2018 → 2020

Multi-year overview

Every figure with its change against the year before

▲ rise ▼ fall

Line20192020202320242025Trend

Equity€-2.67M-€-2.71M▼ 1.2%€-2.91M▼ 7.7%€-3.07M▼ 5.3%€-3.18M▼ 3.8%

Operating result€-11k-€-6k▲ 45.3%€-14k▼ 131%€-14k▲ 0.5%€-15k▼ 5.7%

Net result€-37k-€-32k▲ 12.6%€-123k▼ 283%€-153k▼ 24.3%€-115k▲ 24.7%

Result per fiscal year

Operating resultNet result

The operating result stays negative: a loss of €15k in 2025 against €14k in 2024; the loss grows and 2025 has the lowest result in the available series.

Key figures and ratios

2025 value · change against 2024

Debt to equity

-1.00=

2024 · -1.00

Debt

€3.18M▲

2024 · €3.07M

Debt ≤ 1 year

€3.18M▲

2024 · €3.07M

Green means a favourable move, even when the figure itself falls: as with debt or debt to equity.

Filed annual accounts As filed with the NBB · 2025 against 2024 · 28 lines

Balance sheet Code20242025

Equity and liabilities

Total equity and liabilities10/49€0€0=

Equity10/15€-3.07M€-3.18M▼

Contributions10/11€62k€62k=

Capital10€62k€62k=

Issued capital100€62k€62k=

Reserves13€2k€2k=

Non-distributable reserves130/1€2k€2k=

Legal reserve130€2k-

Reserves not available under the articles1311-€2k

Profit (loss) carried forward14€-3.13M€-3.25M▼

Amounts payable17/49€3.07M€3.18M▲

Amounts payable within one year42/48€3.07M€3.18M▲

Trade debts44€13k€14k▲

Suppliers440/4€13k€14k▲

Other amounts payable47/48€3.05M€3.17M▲

Income statement Code20242025

Operating charges60/66A€14k€15k▲

Services and other goods61€14k€14k▲

Non-recurring operating charges66A-€545

Operating profit (loss)9901€-14k€-15k▼

Financial charges65/66B€140k€101k▼

Recurring financial charges65€140k€101k▼

Debt charges650€139k€100k▼

Other financial charges652/9€790€689▼

Profit (loss) for the period before taxes9903€-153k€-115k▲

Profit (loss) for the period9904€-153k€-115k▲

Profit (loss) for the period to be appropriated9905€-153k€-115k▲

Appropriation of the result

Profit (loss) to be appropriated9906€-3.13M€-3.25M▼

Profit (loss) brought forward from the previous period14P€-2.98M€-3.13M▼

The notes to these accounts (9 items: statements of assets and debts, cost breakdowns, rights and commitments) are not shown here.

Download as CSV

Timeline · acts, filings and financial milestones

All 36Financial 1Gazette 25Filings 10

Next filing, fiscal year 2026, expected by 31-07-2027

2026

07-07

NBB filing Annual accounts filed

fiscal year 2025 · full schema

02-07

State Gazette act Resignations: DOCPHARMA BV, Viatris GX BV and Deloitte Bedrijfsrevisoren BV

Reappointments: DOCPHARMA BV, Viatris GX BV and Deloitte Bedrijfsrevisoren BV · Permanent representatives: Tomasz Buczek, Arun Narayan and Tom Renders · Mandate compensation14 facts ▸

General meeting, 18-06-2026
Director resignation, DOCPHARMA BV (managing director)
Director resignation, Viatris GX BV (director)
Director reappointment, DOCPHARMA BV (managing director)
Director reappointment, Viatris GX BV (director)
Mandate compensation, DOCPHARMA BV
Mandate compensation, Viatris GX BV
Permanent representative, Tomasz Buczek
Permanent representative, Arun Narayan
Director resignation, Deloitte Bedrijfsrevisoren BV (statutory auditor)
Auditor reappointment, Deloitte Bedrijfsrevisoren BV
Permanent representative, Tom Renders
+2 further facts in this act

2025

10-12

State Gazette act Permanent representative: Arun Narayan

Power of attorney4 facts ▸

Board meeting, 25-11-2025
Permanent representative, Arun Narayan
Power of attorney, Johan Lagae
Power of attorney, Els Bruls

10-07

State Gazette act Permanent representative: Tomasz Buczek

2 facts ▸

Board meeting, 23-06-2025
Permanent representative, Tomasz Buczek

27-06

NBB filing Annual accounts filed

fiscal year 2024 · full schema

2024

31-12

Financial Weakest financial yearnet €-153k

Net result drops to €-153k, the lowest in the series; recovery starts the following year.

27-06

NBB filing Annual accounts filed

fiscal year 2023 · full schema

21-03

State Gazette act Permanent representative: Matthew Salzmann

2 facts ▸

Board meeting, 28-02-2024
Permanent representative, Matthew Salzmann

15-02

State Gazette act Statutes amendment

Capital4 facts ▸

General meeting, 26-12-2023
Statutes amendment
Statutes amendment
Capital, €62.000

2023

11-07

State Gazette act Reappointment: Deloitte Bedrijfsrevisoren BV (statutory auditor)

Permanent representative: Gert Vanhees · Power of attorney5 facts ▸

General meeting, 28-06-2023
Auditor reappointment, Deloitte Bedrijfsrevisoren BV (statutory auditor)
Permanent representative, Gert Vanhees
Power of attorney, Johan Lagae
Power of attorney, Els Bruls

10-07

NBB filing Annual accounts filed

fiscal year 2022 · full schema

2022

07-07

NBB filing Annual accounts filed

fiscal year 2021 · full schema

Show earlier events

2021

13-07

NBB filing Annual accounts filed

fiscal year 2020 · full schema

10-05

State Gazette act Permanent representative: L. Birbuet

Resignation: José Cotarelo (permanent representative)3 facts ▸

Board meeting, 31-03-2021
Permanent representative, L. Birbuet (bestuurder bij aktuapharma)
Director resignation, José Cotarelo (permanent representative)

2020

14-07

State Gazette act Reappointments: Docpharma BV, Mylan BV and Deloitte Bedrijfsrevisoren

Mandate compensation6 facts ▸

General meeting, 18-06-2020
Director reappointment, Docpharma BV (director)
Director reappointment, Mylan BV (director)
Mandate compensation, Docpharma BV
Mandate compensation, Mylan BV
Auditor reappointment, Deloitte Bedrijfsrevisoren

09-07

NBB filing Annual accounts filed

fiscal year 2019 · full schema

2019

09-07

NBB filing Annual accounts filed

fiscal year 2018 · full schema

08-02

State Gazette act Permanent representatives: José Cotarelo and Vincent Verschraegen

3 facts ▸

Board meeting, 20-12-2018
Permanent representative, José Cotarelo
Permanent representative, Vincent Verschraegen

2018

04-07

NBB filing Annual accounts filed

fiscal year 2017 · full schema

2017

19-09

State Gazette act Reappointment: Deloitte Bedrijfsrevisoren (statutory auditor)

2 facts ▸

General meeting, 30-08-2017
Auditor reappointment, Deloitte Bedrijfsrevisoren

31-08

NBB filing Annual accounts filed

fiscal year 2016 · full schema · 31 days late

26-04

State Gazette act Permanent representatives: M. Von Wülfing and A. van 't Hullenaar

3 facts ▸

Board meeting, 16-03-2017
Permanent representative, M. Von Wülfing
Permanent representative, A. van 't Hullenaar

2016

15-09

State Gazette act Permanent representative: Jens Neuschaefer

2 facts ▸

Board meeting, 30/08/2016
Permanent representative, Jens Neuschaefer

02-05

State Gazette act Permanent representative: Ivo D'Angelo

2 facts ▸

Board meeting, 11-04-2016
Permanent representative, Ivo D'Angelo

2015

25-09

State Gazette act Permanent representatives: Yves Brigode and Jacek Glinka

4 facts ▸

Board meeting, 31-08-2015
Permanent representative, Yves Brigode (permanent representative)
Board meeting, 09-09-2015
Permanent representative, Jacek Glinka (permanent representative)

29-01

State Gazette act Resignation: Gary Sphar (director)

Appointment: Mylan BVBA (director) · Mandate compensation · Power of attorney5 facts ▸

General meeting, 31-12-2014
Director resignation, Gary Sphar (director)
Director appointment, Mylan BVBA (director)
Mandate compensation, Mylan BVBA
Power of attorney, Karen Laevaert

2014

23-07

State Gazette act Reappointments: Docpharma BVBA (director) and Deloitte Bedrijfsrevisoren (statutory auditor)

Mandate compensation · Power of attorney · Representation6 facts ▸

General meeting, 19-06-2014
Director reappointment, Docpharma BVBA (director)
Mandate compensation, Docpharma BVBA
Auditor reappointment, Deloitte Bedrijfsrevisoren
Power of attorney, Karen Laevaert
Representation, vertegenwoordigd door mevrouw Khadija Badli

13-02

State Gazette act Permanent representative: Khadija Badli

2 facts ▸

Board meeting, 17-12-2013
Permanent representative, Khadija Badli

2013

24-10

State Gazette act Permanent representatives: Pascale Engelen and Steen Vangsgaard

Power of attorney4 facts ▸

Board meeting, 24-09-2013
Permanent representative, Pascale Engelen
Permanent representative, Steen Vangsgaard
Power of attorney, Karen Laevaert

30-05

State Gazette act Resignation: Kristin A Kolesar (director)

Appointment: Gary Elmer SPHAR (director) · Mandate compensation4 facts ▸

General meeting, 06-05-2013
Director resignation, Kristin A Kolesar (director)
Director appointment, Gary Elmer SPHAR (director)
Mandate compensation, Gary Elmer SPHAR

2011

12-08

State Gazette act Resignation: Seshan Srinivasan (director)

Appointments: Kristin Ann KOLESAR (director) and Docpharma BVBA (afgevaardigd bestuurder) · Permanent representative: Pascale Engelen · Reappointment: Deloitte Bedrijfsrevisoren BV ovv CVBA (statutory auditor)10 facts ▸

General meeting, 01-07-2011
Director resignation, Seshan Srinivasan (director)
Director appointment, Kristin Ann KOLESAR (director)
Mandate compensation, Kristin Ann KOLESAR
Board meeting, 08-07-2011
Permanent representative, Pascale Engelen (permanent representative)
Director appointment, Docpharma BVBA (afgevaardigd bestuurder)
Mandate compensation, Docpharma BVBA
General meeting, 20-07-2011
Auditor reappointment, Deloitte Bedrijfsrevisoren BV ovv CVBA

2010

12-10

State Gazette act Permanent representative: Vincent Bouldoires

Resignation: Prasad Nimmagadda (director) · Power of attorney4 facts ▸

Board meeting, 20-05-2010
Permanent representative, Vincent Bouldoires
Power of attorney, Vincent Bouldoires
Director resignation, Prasad Nimmagadda

20-01

State Gazette act Statutes amendment

3 facts ▸

General meeting, 28-12-2009
Statutes amendment
Statutes amendment

08-01

State Gazette act Registered office

Registered-office move2 facts ▸

Board meeting, 11-12-2009
Registered-office move, Terhulpsesteenweg 6A, 1560 Hoeilaart

2006

18-09

State Gazette act Resignation: Stijn Van Rompay (director)

Appointment: SVR Invest BVBA (director) · Permanent representative: Stijn Van Rompay4 facts ▸

General meeting, 18-11-2005
Director resignation, Stijn Van Rompay (director)
Director appointment, SVR Invest BVBA (director)
Permanent representative, Stijn Van Rompay

15-05

State Gazette act Capital & shares · Statutes amendment · Restructuring

Demerger · Share issue · Accounting effect12 facts ▸

General meeting, 30-03-2006
Demerger, partial, Productie en Voorraadbeheer
Share issue, new shares, 15431
Accounting effect, 01-07-2005
Capital decrease, €1.543.118,97
Capital increase, €43.334,84
Capital, €62.000
Power of attorney, Laurent MEUR
Power of attorney, Steven Peters
Power of attorney, Koen Feyaerts
Power of attorney, Elke Janssens
Power of attorney, Jesse Verbist

Financial milestoneState Gazette actNBB filingFinancial milestones sit on the fiscal year-end date, not the filing date.

Directors · office · real estate

Directors

6 directors, no change since 2026

DOCPHARMA

Managing director · since 18-06-2026 · Private limited company · perm. rep.: Tomasz Buczek

Current

Viatris GX

Director · since 18-06-2026 · Private limited company · perm. rep.: Arun Narayan

Current

Gary Elmer SPHAR

Director · since 06-05-2013

Not recently confirmed

Docpharma BVBA

Afgevaardigd bestuurder · since 08-07-2011 · Legal entity · perm. rep.: Pascale Engelen

Not recently confirmed

Kristin Ann KOLESAR

Director · since 01-07-2011

Not recently confirmed

SVR Invest BVBA

Director · since 18-11-2005 · Legal entity · perm. rep.: Stijn Van Rompay

Not recently confirmed

18-06-2026 DOCPHARMA: Reappointed as Managing director

18-06-2026 Viatris GX: Reappointed as Director

01-02-2021 Jose Cotarelo: Resigned as Permanent representative

18-06-2020 DOCPHARMA: Mandate renewed as Director

18-06-2020 Viatris GX: Mandate renewed as Director

Full history in the Timeline (16 changes) →

Location & real-estate footprint

Registered office, Hoeilaart · 1 establishment unit since 1998

establishment The establishment unit on the map

Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Terhulpsesteenweg 6A1560 Hoeilaart

Ground area

3,821 m²

Building footprint

921 m²

Volume, LiDAR

10,579 m³

Parcel 23033C0075/00L019, Flanders · tallest building 14.7 m, ±4 floors. Linked by address, not a title deed.

1 establishment unit

Terhulpsesteenweg 6A, 1560 Hoeilaart

Manufacture of basic metals

since 19982.087.440.889

1 parcel

Flanders 1 (100%)

Parcel (capakey)	Region	Area	Buildings	Height / fl.
23033C0075/00L019	Flanders	3,821 m²	1 · 921 m²	14.7 m · 4 fl.

Linked by address, not proof of ownership

Methodology

via registered seat: 1

1 of 1 parcel with an exact address match; the rest are indicative.

Linked through address data, this is not proof of ownership.

Statutory auditor

1 auditor

Deloitte Bedrijfsrevisoren/Réviseurs d’EntreprisesCurrent

Auditor · represented by Tom Renders

19-06-2014 → present

Show 1 earlier auditors

Deloitte Bedrijfsrevisoren, BV ovv CVBA

Auditor

succeeded by Deloitte Bedrijfsrevisoren/Réviseurs d’Entreprises in 2014

01-07-2011 → 19-06-2014

Articles of association

Purpose

Het zoeken naar nieuwe farmaceutische producten, het verbeteren van bestaande toonbankproducten en geneesmiddelen, het laten vervaardigen of zelf vervaardigen van deze producten…

Full purpose

Het zoeken naar nieuwe farmaceutische producten, het verbeteren van bestaande toonbankproducten en geneesmiddelen, het laten vervaardigen of zelf vervaardigen van deze producten, import en export van farmaceutische producten en aanverwanten, het commercialiseren op de Belgische en buitenlandse markt. De vennootschap heeft tot voorwerp het verrichten van alle diensten die rechtstreeks of onrechtstreeks met deze bedrijvigheid verband houden. Zij mag deelnemen, participeren of tussenkomen in andere ondernemingen of vennootschappen...

according to the deed of 15-02-2024

Structure & network

Connections & network

1 connected company

Linked via shared directors

ORTHOSPINE

Shared corporate director

→

Acquisitions and mergers

1 transaction

Split off to:VALUE PHARMA INTERNATIONAL

BE 0475.603.470partial demerger · State Gazette act of 15-05-2006

Capital and shareholders

Capital over the years

15-02-2024 Capital stated in the act · 62,000 EUR · 120,000 shares
15-05-2006 Capital reduction of 1,543,118.97 EUR
15-05-2006 Capital increase of 43,334.84 EUR · to 62,000 EUR · in cash

Company data · Crossroads Bank

Identification

Legal formPublic limited company

Founded16-06-1998

Fiscal year end31-12

Sources

Crossroads Bank for EnterprisesNational Bank · 27 filingsAddress and cadastre registers

Scores and ratios are computed by Checked and are not a credit decision.